Nephrogenous cyclic AMP, adenylate cyclase-stimulating activity, and the humoral hypercalcemia of malignancy.
暂无分享,去创建一个
A. F. Stewart | A. Broadus | W. Burtis | K. Insogna | Andrew F. Stewart | J. Godsall | J. W. Godsall
[1] A. C. Webb,et al. Messenger ribonucleic acid from tumors associated with humoral hypercalcemia of malignancy directs the synthesis of a secretory parathyroid hormone-like peptide. , 1985, Endocrinology.
[2] G. Mundy,et al. Tumor products and the hypercalcemia of malignancy. , 1985, The Journal of clinical investigation.
[3] R. Baron,et al. Squamous carcinoma model of humoral hypercalcemia of malignancy. , 1984, Endocrinology.
[4] M. J. Moore,et al. The hypercalcemia of cancer. Clinical implications and pathogenic mechanisms. , 1984, The New England journal of medicine.
[5] R. Baron,et al. Biochemical and histomorphometric characterization of a rat model for humoral hypercalcemia of malignancy. , 1984, Endocrinology.
[6] Gideon,et al. Factors associated with humoral hypercalcemia of malignancy stimulate adenylate cyclase in osteoblastic cells. , 1983, The Journal of clinical investigation.
[7] G. Mundy,et al. Absence of parathyroid hormone messenger RNA in nonparathyroid tumors associated with hypercalcemia. , 1983, The New England journal of medicine.
[8] A. F. Stewart,et al. Identification of adenylate cyclase-stimulating activity and cytochemical glucose-6-phosphate dehydrogenase-stimulating activity in extracts of tumors from patients with humoral hypercalcemia of malignancy. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[9] G. Strewler,et al. Human renal carcinoma cells produce hypercalcemia in the nude mouse and a novel protein recognized by parathyroid hormone receptors. , 1983, The Journal of clinical investigation.
[10] R. Baron,et al. Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. , 1982, The Journal of clinical endocrinology and metabolism.
[11] A. Broadus,et al. Hypercalcemia associated with gynecologic malignancies: Biochemical characterization , 1982, Cancer.
[12] S. Tuma,et al. Radioimmunoassay for the middle region of human parathyroid hormone using an homologous antiserum with a carboxy-terminal fragment of bovine parathyroid hormone as radioligand. , 1982, The Journal of clinical endocrinology and metabolism.
[13] A. F. Stewart,et al. Malignancy-associated hypercalcemia: evaluation with a cytochemical bioassay for parathyroid hormone. , 1981, The Journal of clinical endocrinology and metabolism.
[14] O. Clark,et al. Endogenous biologically active human parathyroid hormone: measurement by a guanyl nucleotide-amplified renal adenylate cyclase assay. , 1981, The Journal of clinical endocrinology and metabolism.
[15] F. Singer,et al. Urinary and nephrogenous adenosine 3',5'-monophosphate in the hypercalcemia of malignancy. , 1981, The Journal of clinical endocrinology and metabolism.
[16] A. F. Stewart,et al. Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. , 1980, The New England journal of medicine.
[17] H. Wahner,et al. Scintigraphic evaluation of the skeleton in multiple myeloma. , 1980, Mayo Clinic proceedings.
[18] Patricia A. Johnson,et al. Elevated nephrogenous cyclic AMP with normal serum parathyroid hormone levels in patients with lung cancer. , 1980, The Journal of clinical endocrinology and metabolism.
[19] E. Siris,et al. Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma. , 1980, The New England journal of medicine.
[20] R. Bockman,et al. Comparison of commercially available parathyroid hormone immunoassays in the differential diagnosis of hypercalcemia due to primary hyperparathyroidism or malignancy. , 1979, Annals of internal medicine.
[21] R. Coombes,et al. Calcium metabolism in cancer. Studies using calcium isotopes and immunoassays for parathyroid hormone and calcitonin , 1976, Cancer.
[22] J. Habener,et al. Parathyroid hormone secretion in vivo. Demonstration of a calcium-independent nonsuppressible component of secretion. , 1976, The Journal of clinical investigation.
[23] B. Riggs,et al. Radioimmunoassay of parathyroid hormone in hypercalcemic patients with malignant disease. , 1974, The American journal of medicine.
[24] J. Nelson,et al. The chloride-phosphate ratio in hypercalcemia. , 1974, Annals of internal medicine.
[25] J. Potts,et al. Nonparathyroid humoral hypercalcemia in patients with neoplastic diseases. , 1973, The New England journal of medicine.
[26] T. Nemoto,et al. Phosphaturia in hypercalcemic breast cancer patients. , 1972, The Journal of clinical endocrinology and metabolism.
[27] B. Riggs,et al. Immunologic differentiation of primary hyperparathyroidism from hyperparathyroidism due to nonparathyroid cancer. , 1971, The Journal of clinical investigation.
[28] K. Kivirikko,et al. Modifications of a specific assay for hydroxyproline in urine. , 1967, Analytical biochemistry.
[29] H. O. Heinemann. Metabolic alkalosis in patients with hypercalcemia. , 1965, Metabolism: clinical and experimental.
[30] A. F. Stewart,et al. Elevations in circulating 1,25-dihydroxyvitamin D in three patients with lymphoma-associated hypercalcemia. , 1985, The Journal of clinical endocrinology and metabolism.
[31] E. Frenkel,et al. Hypercalcemia associated with increased serum calcitriol levels in three patients with lymphoma. , 1984, Annals of internal medicine.
[32] R. Horst,et al. A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: application to clinical studies. , 1984, The Journal of clinical endocrinology and metabolism.
[33] A. Broadus. Nephrogenous cyclic AMP. , 1981, Recent progress in hormone research.